Impact of Tremor on Patients With Early Stage Parkinson's Disease

Lauren E Heusinkveld, Mallory L Hacker, Maxim Turchan, Thomas L Davis, David Charles, Lauren E Heusinkveld, Mallory L Hacker, Maxim Turchan, Thomas L Davis, David Charles

Abstract

Tremor is one of the most visible features of Parkinson's disease (PD), and the majority of PD patients experience tremor during the course of the disease. However, the distress caused by this cardinal motor feature for patients early in the course of their PD is commonly underappreciated. People living with early stage PD often experience intense embarrassment and difficulties due to their tremor that limit social interactions, and tremor frequently interferes with the ability to perform activities of daily living and simple tasks at home and work. Although tremor is primarily managed with medications, both tremor response and satisfaction with medical therapy are highly variable. This review offers an overview of reports of the patient experience of tremor in early stage PD and current management options for this cardinal motor feature.

Keywords: Parkinson's disease; deep brain stimulation; patient perspectives; tremor; tremor management.

References

    1. National Parkinson Foundation About Parkinson Disease. Available online at: (Accessed February 15, 2016).
    1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. . Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2007) 68:384–6. 10.1212/01.wnl.0000247740.47667.03
    1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA (2014) 311:1670–83. 10.1001/jama.2014.3654
    1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatr. (2008) 79:368–76. 10.1136/jnnp.2007.131045
    1. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. (1993) 50:140–8. 10.1001/archneur.1993.00540020018011
    1. Martin WE, Loewenson RB, Resch JA, Baker AB. Parkinson's disease. Clinical analysis of 100 patients. Neurology (1973) 23:783–90.
    1. Pal PK, Samii A, Calne DB. Cardinal features of early Parkinson's disease. In: Factor SA, Weiner WJ. editors. Parkinson's Disease Diagnosis and Clinical Management. New York, NY: Demos Medical Publishing, Inc; (2002). p. 41–56.
    1. Elble RJ, Koller WC. Parkinson tremor. In: Elble RJ, Koller WC. editors. Tremor. Baltimore, MD: Johns Hopkins University Press; (1990). p. 118–9.
    1. Marsden CD. Origins of normal and pathological tremor. In: Findley LJ, Capildeo R, Movement Disorders: Tremor. London: Palgrave Macmillan UK; (1984). p 37–84.
    1. Findley LJ, Gresty MA, Halmagyi GM. Tremor, the cogwheel phenomenon and clonus in Parkinson's disease. J Neurol Neurosurg Psychiatr. (1981) 44:534–46.
    1. Hariz GM, Limousin P, Hamberg K. “DBS means everything–for some time.” Patients' perspectives on daily life with deep brain stimulation for Parkinson's disease. J Parkinsons Dis. (2016) 6:335–47. 10.3233/JPD-160799
    1. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. . Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. (2004) 19:1020–8. 10.1002/mds.20213
    1. Uebelacker LA, Epstein-Lubow G, Lewis T, Broughton MK, Friedman JH. A survey of Parkinson's disease patients: most bothersome symptoms and coping preferences. J Parkinsons Dis. (2014) 4:717–23. 10.3233/JPD-140446
    1. Politis M, Wu K, Molloy SG, Bain P, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord. (2010) 25:1646–51. 10.1002/mds.23135
    1. Coelho M, Marti MJ, Tolosa E, Ferreira JJ, Valldeoriola F, Rosa M, et al. . Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol. (2010) 257:1524–32. 10.1007/s00415-010-5566-8
    1. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord. (2006) 21:1123–30. 10.1002/mds.20897
    1. Nijhof G. Parkinson's Disease as a problem of shame in public appearance. Sociol Health Illness (1995) 17:193–205. 10.1111/1467-9566.ep10933386
    1. Louis ED, Machado DG. Tremor-related quality of life: a comparison of essential tremor vs. Parkinson's disease patients. Parkinsonism Relat Disord. (2015) 21:729–35. 10.1016/j.parkreldis.2015.04.019
    1. Louis ED. More time with tremor: the experience of essential tremor versus Parkinson's disease patients. Mov Disord Clin Pract. (2016) 3:36–42. 10.1002/mdc3.12207
    1. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. (2001) 58:1611–5. 10.1001/archneur.58.10.1611
    1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology (2000) 54:S21–3. 10.1212/WNL.54.11.21A
    1. Murphy R, Tubridy N, Kevelighan H, O'Riordan S. Parkinson's disease: how is employment affected? Ir J Med Sci. (2013) 182:415–9. 10.1007/s11845-013-0902-5
    1. Shi J, Liu J, Qu Q. Handedness and dominant side of symptoms in Parkinson's disease. Med Clin. (2014) 142:141–4. 10.1016/j.medcli.2012.11.028
    1. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med. (2005) 353:1021–7. 10.1056/NEJMcp043908
    1. Henderson JM, Yiannikas C, Morris JG, Einstein R, Jackson D, Byth K. Postural tremor of Parkinson's disease. Clin Neuropharmacol. (1994) 17:277–85.
    1. Xia R, Mao Z-H. Progression of motor symptoms in Parkinson's disease. Neurosci Bull. (2012) 28:39–48. 10.1007/s12264-012-1050-z
    1. Elias WJ, Shah BB. Tremor. JAMA (2014) 311:948–54. 10.1001/jama.2014.1397
    1. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. . Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. (2013) 20:5–15. 10.1111/j.1468-1331.2012.03866.x
    1. Oertel WH, Fahn S. Parkinsonism. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C. editors. Neurological Disorders: Course and Treatment. San Diego, CA: Academic Press; (2003). p. 1021–1079.
    1. Yahr MD, Duvoisin RC. Drug therapy of parkinsonism. N Engl J Med. (1972) 287:20–4. 10.1056/NEJM197207062870105
    1. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. (2006) 5:677–87. 10.1016/S1474-4422(06)70521-X
    1. Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC. Cognitive stress reduces the effect of levodopa on parkinson's resting tremor. CNS Neurosci Ther. (2017) 23:209–15. 10.1111/cns.12670
    1. Marjama-Lyons J, Koller W. Tremor-predominant Parkinson's Disease. Drugs Aging (2000) 16:273–8. 10.2165/00002512-200016040-00003
    1. Davidson MB, McGhee DJM, Counsell CE. Comparison of patient rated treatment response with measured improvement in Parkinson's disease. J Neurol Neurosurg Psychiatr. (2012) 83:1001–5. 10.1136/jnnp-2012-302741
    1. Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, et al. . Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 128:2240–9. 10.1093/brain/awh571
    1. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, et al. . Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology (1998) 51:850–855.
    1. Herzog J, Volkmann J, Krack P, Kopper F, Pötter M, Lorenz D, et al. . Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord. (2003) 18:1332–7. 10.1002/mds.10518
    1. Buhmann C, Vettorazzi E, Oehlwein C, Rikkers F, Poetter-Nerger M, Gulberti A, et al. . Impact of deep brain stimulation on daily routine driving practice in patients with Parkinson's disease. Parkinsons Dis. (2015) 2015:608961. 10.1155/2015/608961
    1. Koller WC, Vetere-Overfield B, Barter R. Tremors in early Parkinson's disease. Clin Neuropharmacol. (1989) 12:293–7.
    1. Charles D, Konrad PE, Neimat JS, Molinari AL, Tramontana MG, Finder SG, et al. . Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. Parkinsonism Relat Disord. (2014) 20:731–7. 10.1016/j.parkreldis.2014.03.019
    1. Hacker ML, DeLong MR, Turchan M, Heusinkveld LE, Ostrem JL, Molinari AL, et al. . Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. Neurology (2018). [Epub ahead of print]. 10.1212/WNL.0000000000005903
    1. Pandey S, Srivanitchapoom P. Levodopa-induced Dyskinesia: Clinical features, pathophysiology, and medical management. Ann Indian Acad Neurol. (2017) 20:190–8. 10.4103/aian.AIAN_239_17
    1. Artigas NR, Striebel VLW, Hilbig A, Rieder CR de M. Evaluation of quality of life and psychological aspects of Parkinson's disease patients who participate in a support group. Dement Neuropsychol. (2015) 9:295–300. 10.1590/1980-57642015DN93000013
    1. Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease. BMC Psychiatry (2014) 14:19. 10.1186/1471-244X-14-19
    1. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. . Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry (2011) 168:1066–74. 10.1176/appi.ajp.2011.10111669
    1. Farabaugh A, Locascio JJ, Yap L, Growdon J, Fava M, Crawford C, et al. . Cognitive–behavioral therapy for patients with parkinson's disease and comorbid major depressive disorder. Psychosomatics (2010) 51:124–9. 10.1016/S0033-3182(10)70672-1
    1. Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study. Mov Disord. (2007) 22:946–52. 10.1002/mds.21455
    1. Calleo JS, Amspoker AB, Sarwar AI, Kunik ME, Jankovic J, Marsh L, et al. . A pilot study of a cognitive-behavioral treatment for anxiety and depression in patients with Parkinson disease. J Geriatr Psychiatry Neurol. (2015) 28:210–7. 10.1177/0891988715588831
    1. Egan SJ, Laidlaw K, Starkstein S. Cognitive behaviour therapy for depression and anxiety in parkinson's disease. J Parkinsons Dis. (2015) 5:443–51. 10.3233/JPD-150542
    1. Clarke CE, Patel S, Ives N, Rick CE, Dowling F, Woolley R, et al. Collaborative Group. Physiotherapy and occupational therapy vs no therapy in mild to moderate parkinson disease: a randomized clinical trial. JAMA Neurol. (2016) 73:291–9. 10.1001/jamaneurol.2015.4452
    1. Clarke CE, Patel S, Ives N, Rick CE, Woolley R, Wheatley K, et al. . Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB). Health Technol Assess. (2016) 20:1–96. 10.3310/hta2063

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться